PLRX - NASDAQ

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc.

PLRX·NASDAQ

$1.18

-1.7%
HealthcareBiotechnology

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$73.07M
EPS-2.4300
P/E Ratio-0.49
Earnings Date08/06/2026
Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. Fair Value Envelope

PLRX · NASDAQ

Our analysis suggests that PLRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.18, this represents a potential HIDDEN relative to our calculated worth for Pliant Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.18

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$2.3B
+ Cash & Equivalents$45.4M
Firm Value-$2.3B
- Debt$29.1M
Equity Value-$2.3B
/ Shares Outstanding61,388,154B
DCF Value-$37
OVERVALUED BY 3256%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$153.0M
-$182.4M
-$217.5M
-$259.3M
-$309.2M
-$368.7M
-$439.6M
-$524.1M
-$624.8M
-$745.0M
Maintenance CapEx
-$89.2K
-$106.3K
-$126.8K
-$151.2K
-$180.2K
-$214.9K
-$256.2K
-$305.5K
-$364.2K
-$434.2K
Owner Earnings
-$153.1M
-$182.5M
-$217.6M
-$259.5M
-$309.4M
-$368.9M
-$439.8M
-$524.4M
-$625.2M
-$745.4M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$141.8M
-$156.5M
-$172.8M
-$190.7M
-$210.6M
-$232.5M
-$256.6M
-$283.3M
-$312.8M
-$345.3M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your PLRX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.